ReviewInternational journal of molecular sciences2026
Fifteen Years of the Genome Analysis Toolkit as the De Facto Standard in Short-Read Variant Calling.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Genome Analysis Toolkit (GATK) is a rigorously maintained collection of 430 analysis tools and a core bioinformatics engine. First released in 2010 as a toolkit for next-generation sequencing (NGS) data analysis, GATK remains one of the least celebrated yet foundational tools of the NGS era. By employing state-of-the-art approaches and continuously adapting to the evolving demands of NGS analysis, it has effectively unified the variant calling process worldwide. In a field as rapidly evolving as genomics, it is remarkable that, over a decade later, the same toolkit remains the gold standard. This critical review explores the pre-history of GATK, the reasons for its broad and enduring adoption by the scientific community, its developmental evolution, contributions to science, and future prospects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.